Global E-Health Forum - Hamburg 2011

11 - 13 October 2011, Hamburg, Germany.
Improving the quality of healthcare, increasing the efficiency of the systems and ensuring patient empowerment - these are the common goals worldwide when discussing the necessary transformation of the systems in order to guarantee a sustainable healthcare delivery in the future. The Global E-Health Forum - Hamburg 2011 will represent major stakeholders involved in designing personalized healthcare.

"E-Health is increasingly seen as a key enabler for this transformation," so Ljubisav Matejevic, founder and honorary chairman of the Global E-Health Forum. "And as a key enabler for the evolution process towards personalized healthcare. Healthcare that is proactive, instead of reactive, gives the patients the opportunity and the responsibility to become more involved in their own health. The ultimate goal will be to shape preventive and diagnostic care to match each person's unique characteristics."

The initiators of the Global E-Health Forum - Hamburg Chamber of Commerce, IBM and ICC - have developed this platform to discuss e-health strategies, best practices and new services/patient-centric approaches in a global context. While the main target groups consist of CEOs, CIOs and CFOs of hospitals and clinics, the comprehensive program will also attract representatives from governmental bodies, health insurance organizations, service providers, influencers from hospital and health management associations as well as representatives from universities/research institutes. Canada supports the Global E-Health Forum - Hamburg 2011 as partner country.

The first two conference days will feature speakers from all over the globe:

  • Richard C. Alvarez, President and Chief Executive Officer of Canada Health Infoway, with "Transforming Healthcare in Canada through E-Health"
  • Prof. WEN Ze Huai, (M. D.), Key Unit of Methodology in Clinical Research, Guangdong Traditional Chinese Medicine International Clinical Research Center, Research Center Guangdong Academy of Chinese Medical Sciences, with "Designing Personalized Healthcare for Integrated Medicine by Using Information Technology"
  • Dr. Eric M. Liederman, Director of Medical Informatics, The 45 Permanente Medical Group (USA), with "Balancing Privacy Protection with Patient Care"
  • Prof. Dr. Roland Eils, Division Head "Theoretical Bioinformatics", German Cancer Research Center (DKFZ) and Manuela Mueller-Gerndt, Healthcare Leader, IMT Germany, Smarter Healthcare, IBM Deutschland GmbH with "Oncology as a Key Driver for Cancer Research and Individualized Medicine"
  • Chai Chuah, National Director, National Health Board Business Unit, New Zealand Ministry of Health, with "Sustainable Personalized Healthcare - Challenges and Opportunities"

Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. During the evening reception at the U.S. Consulate General on October 11, there will be manifold opportunity of knowledge and experience exchange as well as networking. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups. The third day is dedicated to guided tours of different hospitals and clinics in Hamburg, three of them being Asklepios clinics. The Asklepios Hospital Group renewed its cooperation partnership with the Global E-Health Forum.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]